Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum

Cancer Genet. 2012 Nov;205(11):594-8. doi: 10.1016/j.cancergen.2012.08.005. Epub 2012 Oct 2.

Abstract

Well-differentiated papillary mesothelioma of the peritoneum (WDPMP) is a rare disease, and many cases are either benign neoplasms or low-graded malignancies; however, a few cases show rapid progressive clinical courses. No effective therapy has yet been established for WDPMP, and the molecular basis of WDPMP tumorigenesis has never been reported. This study shows the malignant transformation of WDPMP in a Japanese female patient, who was alive for 54 months after the initial diagnosis by a laparoscopic biopsy. A molecular analysis of single nucleotide polymorphisms (SNPs), which were located in the neurofibromatosis type 2 (NF2) gene, a tumor suppressor gene assigned to chromosome 22q12.3, revealed the loss of heterozygosity (LOH) of the NF2 gene. Furthermore, SNP analyses determined that LOH was observed in the IL17RA (22q11.1), CHECK2 (22q12.1), and SHANK3 (22q13.3) genes, thus suggesting that NF2 loss occurred through 22q deletions or monosomy 22. The LOH of the NF2 gene was observed in an early stage of WDPMP, thus indicating that LOH of the NF2 gene is an early molecular alteration, and NF2 loss is a molecular mechanism associated not only with malignant pleural mesothelioma, but also with WDPMP.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • DNA Mutational Analysis
  • E2F1 Transcription Factor / genetics*
  • Fatal Outcome
  • Female
  • Genes, Neurofibromatosis 2*
  • Histocytochemistry
  • Humans
  • Loss of Heterozygosity*
  • Mesothelioma / genetics*
  • Mesothelioma / pathology
  • Mesothelioma / surgery
  • Peritoneal Neoplasms / genetics*
  • Peritoneal Neoplasms / pathology
  • Polymorphism, Single Nucleotide

Substances

  • E2F1 Transcription Factor
  • E2F1 protein, human